CRISPR Therapeutics AG (CRSP): Cash & Equivalents
$347.56M
As of 2025-12-31
$291.34M
As of 2026-06-30
+17.9%
3-year compound annual growth
-21.5%
5-year compound annual growth
+8.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $347.56M | +16.5% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $298.26M | -23.4% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $389.48M | +83.8% | 2026-02-12, Balance as of period end |
| 2022-12-31 | $211.88M | -77.0% | 2025-02-11, Balance as of period end |
| 2021-12-31 | $923.03M | -21.0% | 2024-02-21, Balance as of period end |
| 2020-12-31 | $1.17B | +23.8% | 2023-02-21, Balance as of period end |
| 2019-12-31 | $943.77M | +106.7% | 2022-02-15, Balance as of period end |
| 2018-12-31 | $456.65M | +90.5% | 2021-02-16, Balance as of period end |
| 2017-12-31 | $239.76M | -24.0% | 2020-02-12, Balance as of period end |
| 2016-12-31 | $315.52M | +102.3% | 2019-02-25, Balance as of period end |
| 2015-12-31 | $155.96M | n/m | 2018-03-08, Balance as of period end |
| 2014-12-31 | $945.0K | n/a | 2017-03-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗